21 completed, 3 not yet recruiting, 2 recruiting. 15 Phase 3, 10 Phase 2, 4 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 15 | Completed 14, Not yet recruiting 1 |
| Phase 2 | 10 | Completed 8, Not yet recruiting 1, Recruiting 1 |
| Phase 1 | 4 | Completed 2, Not yet recruiting 1, Recruiting 1 |
Follow Vehicle Ophthalmic Solution: new trials by email Literature Review of Vehicle Ophthalmic Solution trials Research Report on Vehicle Ophthalmic Solution
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Phase 2 Study of RCI001 Ophthalmic Solution in Participants With Dry Eye Disease RCI001 Ophthalmic Solution, Placebo Ophthalmic Solution - Dry Eye | Phase 2 | Not yet recruiting | Rudacure | 200 | 2027-09-01 | 2026-06-04 |
| Evaluation of PAN-90806 Eye Drops in Healthy Subjects PAN-90806 Ophthalmic Solution, Vehicle Ophthalmic Solution - Wet Age Related Macular Degeneration, Neovascular (Wet) Age-Related Macular Degeneration | Phase 1 | Not yet recruiting | Zhaoke (Guangzhou) Ophthalmology Pharmaceutical Ltd. | 20 | 2026-09-30 | 2026-08-14 |
| Phase 3, Multi-Center, Randomized, Double-Masked, Placebo-Controlled Study Assessing the Safety and Efficacy of Urcosimod Ophthalmic Solution in Participants With Neuropathic Corneal Pain (NCP). Urcosimod ophthalmic solution is a preservative-free topical ophthalmic product; supplied in unit dose ampoules; administered QID for 12-weeks., Vehicle Ophthalmic Solution - Neuropathic Corneal Pain | Phase 3 | Not yet recruiting | Okyo Pharma Ltd | 111 | 2026-09-01 | 2026-09-29 |
| A Multicenter, Randomized, Vehicle-Controlled, Double-Masked to Open-Label Study to Evaluate the Safety and Efficacy of Lacripep in Subjects With Neurotrophic Keratitis Lacripep, Vehicle Ophthalmic Solution - Neurotrophic Keratitis | Phase 2 | Recruiting | TearSolutions, Inc. | 54 | 2026-02-19 | 2026-09-25 |
| A Safety Study of IVMED-85 Ophthalmic Solution in Healthy Adults IVMED-85 ophthalmic solution, Vehicle Ophthalmic Solution - Safety Study | Phase 1 | Recruiting | iVeena Delivery Systems, Inc. | 36 | 2026-02-04 | 2026-02-05 |
| A Trial to Assess the Safety and Efficacy of Subjects With Dry Eye Disease Reproxalap Ophthalmic Solution (0.25%), Vehicle Ophthalmic Solution - Dry Eye Disease | Phase 3 | Completed | Aldeyra Therapeutics, Inc. | 116 | 2024-06-24 | 2025-12-22 |
| A Clinical Trial to Assess the Safety and Efficacy of Subjects With Dry Eye Disease Reproxalap ophthalmic solution (0.25%), Vehicle ophthalmic solution - Dry Eye Disease | Phase 3 | Completed | Aldeyra Therapeutics, Inc. | 421 | 2024-04-29 | 2025-10-01 |
| A Clinical Trial to Assess the Efficacy and Safety of Subjects With Dry Eye Disease Reproxalap Ophthalmic Solution (0.25%), Vehicle Ophthalmic Solution - Dry Eye Disease | Phase 3 | Completed | Aldeyra Therapeutics, Inc. | 132 | 2024-04-09 | 2025-06-05 |
| Efficacy and Safety Evaluation of Tavilermide Ophthalmic Solution for the Treatment of Dry Eye 5% Tavilermide ophthalmic solution, Vehicle ophthalmic solution - Dry Eye Syndromes, Dry Eye Disease | Phase 3 | Completed | Mimetogen Pharmaceuticals USA, Inc. | 642 | 2023-06-28 | 2024-06-10 |
| Safety Study of Tivanisiran to Treat Dry Eye Tivanisiran sodium ophthalmic solution, Vehicle ophthalmic solution - Dry Eye Disease | Phase 3 | Completed | Sylentis, S.A. | 301 | 2022-03-24 | 2026-09-09 |
| A Clinical Trial to Evaluate the Safety and Efficacy of Rreproxalap in Adults With Dry Eye Disease Reproxalap Ophthalmic Solution (0.25%), Vehicle Ophthalmic Solution - Dry Eye Syndromes | Phase 2 | Completed | Aldeyra Therapeutics, Inc. | 63 | 2022-03-09 | 2025-01-15 |
| The INVIGORATE 2 Trial: A Clinical Trial to Assess the Efficacy and Safety of Subjects With Seasonal Allergic Conjunctivitis Reproxalap Ophthalmic Solution (0.25%), Vehicle Ophthalmic Solution - Allergic Conjunctivitis | Phase 3 | Completed | Aldeyra Therapeutics, Inc. | 131 | 2022-01-21 | 2026-05-14 |
| A Phase 3, Multi-Center Study Evaluating PL9643 in Patients with Dry Eye Vehicle Ophthalmic Solution, PL9643 Ophthalmic Solution - Dry Eye, Dry Eye Syndromes | Phase 3 | Completed | Palatin Technologies, Inc | 575 | 2021-12-30 | 2024-10-17 |
| The TRANQUILITY 2 Trial: A Phase 3 Clinical Trial to Assess the Efficacy and Safety in Subjects With Dry Eye Disease Reproxalap Ophthalmic Solution (0.25%), Vehicle Ophthalmic Solution - Dry Eye | Phase 3 | Completed | Aldeyra Therapeutics, Inc. | 361 | 2021-08-28 | 2025-03-18 |
| A Clinical Trial to Assess Subjects With Dry Eye Disease. Reproxalap Ophthalmic Solution (0.25%), Vehicle Ophthalmic Solution - Dry Eye | Phase 2 | Completed | Aldeyra Therapeutics, Inc. | 158 | 2021-06-15 | 2025-02-24 |
| Tivanisiran for Dry Eye in Subjects With Sjögren's Syndrome Tivanisiran sodium ophthalmic solution, Vehicle ophthalmic solution - Dry Eye Disease, Sjögren Syndrome | Phase 3 | Completed | Sylentis, S.A. | 203 | 2021-05-25 | 2024-02-20 |
| The INVIGORATE Trial: A Clinical Trial to Assess the Efficacy and Safety of Subjects With Seasonal Allergic Conjunctivitis. Reproxalap Ophthalmic Solution (0.25%), Vehicle Ophthalmic Solution - Allergic Conjunctivitis | Phase 3 | Completed | Aldeyra Therapeutics, Inc. | 95 | 2019-12-05 | 2024-11-20 |
| Dose Ranging Study to Assess the Efficacy and Safety of Voclosporin Ophthalmic Solution in Subjects With Dry Eye Syndrome 0.05% Voclosporin Ophthalmic Solution (VOS), 0.10% VOS, 0.20% VOS - Dry Eye Syndrome, Keratoconjunctivitis Sicca | Phase 2 / Phase 3 | Completed | Aurinia Pharmaceuticals Inc. | 508 | 2019-10-14 | 2021-12-10 |
| A Methodology Development Clinical Trial of Reproxalap in Subjects With Seasonal Allergic Conjunctivitis Using the Environmental Exposure Chamber Reproxalap Ophthalmic Solution (0.25%), Reproxalap Ophthalmic Solution (0.5%), Vehicle Ophthalmic Solution - Conjunctivitis, Allergic | Phase 1 / Phase 2 | Completed | Aldeyra Therapeutics, Inc. | 70 | 2018-10-02 | 2025-02-24 |
| A Methodology Development Environmental Clinical Trial of Reproxalap in Subjects With Seasonal Allergic Conjunctivitis Reproxalap Ophthalmic Solution (0.25%), Reproxalap Ophthalmic Solution (0.5%), Vehicle Ophthalmic Solution - Allergic Conjunctivitis | Phase 1 / Phase 2 | Completed | Aldeyra Therapeutics, Inc. | 52 | 2018-09-08 | 2025-04-08 |
Showing 20 of 26. Sign in to see all of them.
Dry Eye Syndromes (13) · Conjunctivitis, Allergic (5) · Keratoconjunctivitis Sicca (3) · Blepharoptosis (2) · Eye Pain (2) · Conjunctival Diseases (1) · Corneal Diseases (1) · Corneal Endothelial Cell Loss (1) · Eye Diseases (1) · Glaucoma (1) · Macular Degeneration (1) · Myopia (1) · Ocular Hypertension (1) · Sjogren's Syndrome (1)
Aldeyra Therapeutics, Inc. (12) · RVL Pharmaceuticals, Inc. (2) · Sylentis, S.A. (2) · Allergan (1) · Aurinia Pharmaceuticals Inc. (1) · Biogen (1) · Mimetogen Pharmaceuticals USA, Inc. (1) · Okyo Pharma Ltd (1) · Palatin Technologies, Inc (1) · Rudacure (1) · TearSolutions, Inc. (1) · Zhaoke (Guangzhou) Ophthalmology Pharmaceutical Ltd. (1) · iVeena Delivery Systems, Inc. (1)
United States (19) · Canada (5) · Spain (1)
Brian Dodge (1) · Flavio Mantelli, MD, PhD (1) · Marc Odrich, MD (1) · Mary Palmen (1) · Patricia Couroux, MD (1) · Yuseung Ha (1)
PMID 36729473, PMID 28736340, PMID 33450164, PMID 35585427, PMID 38105911